Background: Activating mutations in PIK3CA, the gene coding for the catalytic subunit (p110α) of phosphoinositide-3-kinase (PI3K), are the most frequent oncogenic alterations in oestrogen receptor-positive (ER+) breast cancer and are also prevalent in other tumour types. PI3Kα inhibitors have recently been shown to be clinically active in ER+ breast cancers harbouring PIK3CA mutations. In early clinical trials we had observed that there was also a population of patients that displayed deep and prolonged clinical benefit. In one such patient, whose tumour we had fully genomically characterized, we detected the presence of double PIK3CA mutations in all metastatic sites and at different times over tumour evolution (Juric, Castel, and Scaltriti Nature 2015).